Characteristics of patients with JAK2 mutations (other than PV/MF/ET)
Diagnosis,*sex, and age, y . | WBCs, × 109/L . | Monocytes, × 109/L . | Bone marrow megakaryocytes . | Splenomegaly . | Cytogenetics . | Time from diagnosis, mo. . | Quantity of JAK2 mutant allele, % . | RAS mutations . |
|---|---|---|---|---|---|---|---|---|
| CML Ph- | ||||||||
| M, 67 | 16.3 | 0.8 | Normal | No | 46XY | 0 | 5 | Negative |
| M, 70 | 12.4 | 0.2 | Hyperplasia | Yes | 46XY | 6 | 44 | ND |
| M, 70 | 29.7 | 1.1 | Hyperplasia | Yes | 46XY | 20 | 59 | Negative |
| CMML | ||||||||
| M, 73 | 39.1 | 7.4 | Hyperplasia | Yes | 46XY | 18 | 9 | Negative |
| M, 55 | 9.5 | 1.5 | Hyperdysplasia | No | 46XY | 0 | 36 | Negative |
| M, 70 | 61.3 | 9.2 | Hyperplasia | Yes | 46XY | 1 | 83 | ND |
| M, 73 | 16.1 | 2.4 | Hyperplasia | No | 46XY | 16 | 40 | ND |
| F, 73 | 22.1 | 5.3 | Hypoplasia | No | 46XX | 0 | 17 | ND |
| F, 68 | 26.6 | 4.5 | Normal | No | 46XX,-7,t(13;21)(q12;q22) | 0 | 48 | Developed later |
| F, 63 | 4.9 | 0.9 | Hyperplasia | Yes | 46,XX,i(X)(p10) | 1 | 47 | ND |
| AML M7 | ||||||||
| M, 52 | 4.0 | 0.1 | Blasts | No | 46XY,del(9)(q22) | 5 | 7 | Negative |
| F, 51 | 0.6 | 0.1 | Hyperdysplasia | Yes | Complex, includes +add(9)(p24) | 3 | 57 | ND |
| MDS-RAEB | ||||||||
| M, 63 | 65.8 | 3.9 | Hyperdysplasia | Yes | 46XY | 10 | 51 | Negative |
Diagnosis,*sex, and age, y . | WBCs, × 109/L . | Monocytes, × 109/L . | Bone marrow megakaryocytes . | Splenomegaly . | Cytogenetics . | Time from diagnosis, mo. . | Quantity of JAK2 mutant allele, % . | RAS mutations . |
|---|---|---|---|---|---|---|---|---|
| CML Ph- | ||||||||
| M, 67 | 16.3 | 0.8 | Normal | No | 46XY | 0 | 5 | Negative |
| M, 70 | 12.4 | 0.2 | Hyperplasia | Yes | 46XY | 6 | 44 | ND |
| M, 70 | 29.7 | 1.1 | Hyperplasia | Yes | 46XY | 20 | 59 | Negative |
| CMML | ||||||||
| M, 73 | 39.1 | 7.4 | Hyperplasia | Yes | 46XY | 18 | 9 | Negative |
| M, 55 | 9.5 | 1.5 | Hyperdysplasia | No | 46XY | 0 | 36 | Negative |
| M, 70 | 61.3 | 9.2 | Hyperplasia | Yes | 46XY | 1 | 83 | ND |
| M, 73 | 16.1 | 2.4 | Hyperplasia | No | 46XY | 16 | 40 | ND |
| F, 73 | 22.1 | 5.3 | Hypoplasia | No | 46XX | 0 | 17 | ND |
| F, 68 | 26.6 | 4.5 | Normal | No | 46XX,-7,t(13;21)(q12;q22) | 0 | 48 | Developed later |
| F, 63 | 4.9 | 0.9 | Hyperplasia | Yes | 46,XX,i(X)(p10) | 1 | 47 | ND |
| AML M7 | ||||||||
| M, 52 | 4.0 | 0.1 | Blasts | No | 46XY,del(9)(q22) | 5 | 7 | Negative |
| F, 51 | 0.6 | 0.1 | Hyperdysplasia | Yes | Complex, includes +add(9)(p24) | 3 | 57 | ND |
| MDS-RAEB | ||||||||
| M, 63 | 65.8 | 3.9 | Hyperdysplasia | Yes | 46XY | 10 | 51 | Negative |
ND indicates not determined.
Diagnostic criteria for Ph-negative CML and CMML were described earlier.17,18